A Phase I Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of XTR003 in Healthy Chinese Volunteers
Latest Information Update: 21 Dec 2021
At a glance
- Drugs XTR 003 (Primary)
- Indications Coronary artery disease
- Focus Adverse reactions
- Sponsors Sinotau Pharmaceuticals
- 02 Dec 2021 New trial record